BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 30662566)

  • 1. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.
    Jin H; He Y; Zhao P; Hu Y; Tao J; Chen J; Huang Y
    Theranostics; 2019; 9(1):265-278. PubMed ID: 30662566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
    Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
    J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of integrin β3 by sustained ERK activity promotes the invasiveness of TGFβ-induced mesenchymal tumor cells.
    Hong SK; Park JR; Kwon OS; Kim KT; Bae GY; Cha HJ
    Cancer Lett; 2016 Jul; 376(2):339-46. PubMed ID: 27085460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M2 polarization of tumor-associated macrophages is dependent on integrin β3 via peroxisome proliferator-activated receptor-γ up-regulation in breast cancer.
    Shu Y; Qin M; Song Y; Tang Q; Huang Y; Shen P; Lu Y
    Immunology; 2020 Aug; 160(4):345-356. PubMed ID: 32311768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteolin reduces the invasive potential of malignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition.
    Ruan JS; Liu YP; Zhang L; Yan LG; Fan FT; Shen CS; Wang AY; Zheng SZ; Wang SM; Lu Y
    Acta Pharmacol Sin; 2012 Oct; 33(10):1325-31. PubMed ID: 22983392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin pretreatment inhibits the lipopolysaccharide-induced epithelial-mesenchymal transition via the downregulation of toll-like receptor 4 and nuclear factor-κB in human biliary epithelial cells.
    Kim Y; Lee EJ; Jang HK; Kim CH; Kim DG; Han JH; Park SM
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1220-8. PubMed ID: 26574150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin attenuates TGF-β1-induced epithelial-mesenchymal transition in human alveolar epithelial cells.
    Yang T; Chen M; Sun T
    Cell Physiol Biochem; 2013; 31(6):863-74. PubMed ID: 23817018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
    Brown WS; Tan L; Smith A; Gray NS; Wendt MK
    Mol Cancer Ther; 2016 Sep; 15(9):2096-106. PubMed ID: 27371729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid reverses epithelial-mesenchymal transition in paclitaxel-resistant cells by inhibiting nuclear factor kappa B and upregulating gap junctions.
    Shi G; Zheng X; Wu X; Wang S; Wang Y; Xing F
    Cancer Sci; 2019 Jan; 110(1):379-388. PubMed ID: 30375704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma.
    Zhu X; Tao X; Lu W; Ding Y; Tang Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):615-624. PubMed ID: 30627776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFR
    Yin W; Yu X; Kang X; Zhao Y; Zhao P; Jin H; Fu X; Wan Y; Peng C; Huang Y
    Small; 2018 Nov; 14(47):e1802372. PubMed ID: 30307695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
    He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
    J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin.
    Dia VP; Pangloli P
    J Cell Physiol; 2017 Feb; 232(2):391-401. PubMed ID: 27198989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.